Study the effect of genistein nanoparticles in treatment of experimental induced osteoporosis in female rats

Abstract

The present study has been designed to investigate the therapeutic effect of genistein nanoparticles at dose 50 mg/kg in female rats with osteoporosis induction. Forty adult female Wister rats were divided randomly into four equal groups. The control group (C) was given 1ml of distilled water daily for 30 consecutive day considers as positive control group. The G1 group was injected of D-galactose (200 mg/kg/day) intraperitoneal for 60 consecutive days for osteoporosis induction. The G2 group was given orally Nano- Genistein at dose 50 mg/kg/day suspended in 1ml of distilled water for 30 consecutive days. The G3 group was injected of D-galactose (200 mg/kg/day) intraperitoneal for 60 consecutive days for osteoporosis induction, then was given orally Nano-Genistein at dose 50 mg/kg/day suspended in 1ml distilled water for 30 consecutive days. At the end of experiment the body weight was taken and then the animals were sacrificed and blood samples were taken from the heart, serum samples were separated from blood for assessment of alkaline phosphatase (ALP), phosphors, calcium, interleukin 6 (IL-6),estradiol(E2)hormone, osteoprotegrin (OPG), Receptor Activator of Nuclear Factor Kappa B Ligand(RANκL), vitamin D3 (VD3) and calcitonin hormone. The study findings revealed a significant differences (p<0.05) in multiple parameters among the experimental groups. The group administered with D- galactose had a substantial reduction in body weight, phosphors, calcium, estradiol(E2) hormone, osteoprotegrin (OPG),vitamin D3 (VD3),calcitonin hormone bone mineral density (BMD), bone mineral content (BMC), trabecular thickness, and bone volume fraction (BV/TV)in comparison to the control group. The Nano-Genistein group demonstrated a notable elevation in these parameters (except estradiol hormone(E2)) in comparison to the control group. Also these parameters were increased in G3 which had osteoporosis and treated with genistein nanoparticles as compared with G1 group. The D- galactose group(G1) had a notable elevation(p<0.05) in alkaline phosphatase (ALP), interleukin 6 (IL-6) and Receptor Activator of Nuclear Factor Kappa B Ligand(RANκL) levels in comparison to the control group. While the nano- genistein group(G2) exhibited a notable reduction in levels of these parameters in comparison to the control group. The G3 also showed a significant reduction(p<0.05)in these parameters as compared with G1group. We can conclude that genistein nanoparticles at dose 50 mg/kg appears to enhance its bioavailability and effectiveness in osteoporosis treatment.